Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis

Halina Offner, Bozena Celnik, Timothy S. Bringman, Denise Casentini-Borocz, Glenn E. Nedwin, Arthur Vandenbark

Research output: Contribution to journalArticle

176 Citations (Scopus)

Abstract

Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.

Original languageEnglish (US)
Pages (from-to)177-184
Number of pages8
JournalJournal of Neuroimmunology
Volume28
Issue number2
DOIs
StatePublished - 1990

Fingerprint

Galactosides
Autoimmune Experimental Encephalomyelitis
Lectins
T-Lymphocytes
Myelin Basic Protein
Poisons
Cytotoxins
Immunosuppressive Agents
Placenta
Autoimmune Diseases
Carrier Proteins
Proteins
Complementary DNA
Transplantation
Escherichia coli
Injections
Therapeutics

Keywords

  • Delayed-type hypersensitivity
  • Experimental autoimmune encephalomyelitis
  • Immunosuppression
  • Myelin basic protein
  • Recombinant β-galactoside binding human immunolectin
  • T cell line

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Neurology
  • Neurology

Cite this

Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. / Offner, Halina; Celnik, Bozena; Bringman, Timothy S.; Casentini-Borocz, Denise; Nedwin, Glenn E.; Vandenbark, Arthur.

In: Journal of Neuroimmunology, Vol. 28, No. 2, 1990, p. 177-184.

Research output: Contribution to journalArticle

Offner, Halina ; Celnik, Bozena ; Bringman, Timothy S. ; Casentini-Borocz, Denise ; Nedwin, Glenn E. ; Vandenbark, Arthur. / Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. In: Journal of Neuroimmunology. 1990 ; Vol. 28, No. 2. pp. 177-184.
@article{61f209206ffc45558e449e173aa65c16,
title = "Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis",
abstract = "Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.",
keywords = "Delayed-type hypersensitivity, Experimental autoimmune encephalomyelitis, Immunosuppression, Myelin basic protein, Recombinant β-galactoside binding human immunolectin, T cell line",
author = "Halina Offner and Bozena Celnik and Bringman, {Timothy S.} and Denise Casentini-Borocz and Nedwin, {Glenn E.} and Arthur Vandenbark",
year = "1990",
doi = "10.1016/0165-5728(90)90032-I",
language = "English (US)",
volume = "28",
pages = "177--184",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis

AU - Offner, Halina

AU - Celnik, Bozena

AU - Bringman, Timothy S.

AU - Casentini-Borocz, Denise

AU - Nedwin, Glenn E.

AU - Vandenbark, Arthur

PY - 1990

Y1 - 1990

N2 - Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.

AB - Human placental tissue contains regulatory molecules that may prevent allo-sensitization. Recently, a 14 kDa β-galactoside binding protein with demonstrated immunoregulatory properties has been cloned using cDNA from human placenta and expressed in Escherichia coli. The present study assesses the ability of this recombinant immunomodulatory lectin (rIML-1), to prevent experimental autoimmune encephalomyelitis (EAE), a paralytic T cell-mediated disease directed against myelin basic protein (BP). Injection or rIML-1 into Lewis rats inhibited the induction of both clinical and histological signs of EAE, apparently by blocking sensitization of encephalitogenic BP-specific T cells and inducing BP-dependent suppressor cells. Because it is neither immunogenic nor toxic, rIML-1 may have application in humans, and would have distinct advantages over unselective cytotoxic immunosuppressive agents used currently in the treatment of autoimmune diseases and transplantation.

KW - Delayed-type hypersensitivity

KW - Experimental autoimmune encephalomyelitis

KW - Immunosuppression

KW - Myelin basic protein

KW - Recombinant β-galactoside binding human immunolectin

KW - T cell line

UR - http://www.scopus.com/inward/record.url?scp=0025309457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025309457&partnerID=8YFLogxK

U2 - 10.1016/0165-5728(90)90032-I

DO - 10.1016/0165-5728(90)90032-I

M3 - Article

C2 - 1694534

AN - SCOPUS:0025309457

VL - 28

SP - 177

EP - 184

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 2

ER -